Hélène Cabanas: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(copy)
(expanded)
Line 5: Line 5:
* 2018, Decreased Expression of [[TRPM3]] and [[mAChRM3]] in the Small Intestine in [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]]<ref>{{Cite journal|last=Marshall-Gradisnik|first=Sonya|author-link=Sonya Marshall-Gradisnik|last2=Fretel|first2=Marshall|last3=Eaton|first3=Natalie|last4=Cabanas|first4=Helene|last5=Balinas|first5=Cassandra|last6=Gopalan|first6=Vinod|last7=Petersen|first7=Daniel|author-link7=Daniel Peterson|last8=Passmore|first8=Rachel|last9=Tang|first9=Kevin|last10= Haque|first10=Mazhar|author-link10=|last11=Lam|first11=Alfred |author-link11=|last12=Staines|first12=Donald|author-link12=Donald Staines|date=2018-05-31|title=Decreased Expression of TRPM3 and mAChRM3 in the Small Intestine in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|url=http://www.scirp.org/journal/PaperInformation.aspx?PaperID=85005&#abstract|journal=International Journal of Clinical Medicine|language=en|volume=09|issue=05|pages=467|doi=10.4236/ijcm.2018.95040|via=|pmc=|pmid=|quote=|author-link2=|access-date=|author-link3=|author-link4=Hélène Cabanas|author-link5=|author-link6=}}</ref> - [http://file.scirp.org/Html/11-2101759_85005.htm (Full text)]
* 2018, Decreased Expression of [[TRPM3]] and [[mAChRM3]] in the Small Intestine in [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]]<ref>{{Cite journal|last=Marshall-Gradisnik|first=Sonya|author-link=Sonya Marshall-Gradisnik|last2=Fretel|first2=Marshall|last3=Eaton|first3=Natalie|last4=Cabanas|first4=Helene|last5=Balinas|first5=Cassandra|last6=Gopalan|first6=Vinod|last7=Petersen|first7=Daniel|author-link7=Daniel Peterson|last8=Passmore|first8=Rachel|last9=Tang|first9=Kevin|last10= Haque|first10=Mazhar|author-link10=|last11=Lam|first11=Alfred |author-link11=|last12=Staines|first12=Donald|author-link12=Donald Staines|date=2018-05-31|title=Decreased Expression of TRPM3 and mAChRM3 in the Small Intestine in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|url=http://www.scirp.org/journal/PaperInformation.aspx?PaperID=85005&#abstract|journal=International Journal of Clinical Medicine|language=en|volume=09|issue=05|pages=467|doi=10.4236/ijcm.2018.95040|via=|pmc=|pmid=|quote=|author-link2=|access-date=|author-link3=|author-link4=Hélène Cabanas|author-link5=|author-link6=}}</ref> - [http://file.scirp.org/Html/11-2101759_85005.htm (Full text)]
* 2018, A systematic review of enteric [[dysbiosis]] in chronic fatigue syndrome/myalgic encephalomyelitis<ref>{{Cite journal|last=Du Preez|first=S.|author-link=|last2=Corbitt|first2=M.|author-link2=|last3=Cabanas|first3=H.|author-link3=Hélène Cabanas|last4=Eaton|first4=N.|author-link4=|last5=Staines|first5=D.|author-link5=Donald Staines|last6=Marshall-Gradisnik|first6=S.|author-link6=Sonya Marshall-Gradisnik|date=2018-12-20|title=A systematic review of enteric dysbiosis in chronic fatigue syndrome/myalgic encephalomyelitis|url=https://doi.org/10.1186/s13643-018-0909-0|journal=Systematic Reviews|volume=7|issue=1|pages=241|doi=10.1186/s13643-018-0909-0|issn=2046-4053|pmc=|pmid=30572962|quote=|via=}}</ref> - [https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-018-0909-0 (Full text)]
* 2018, A systematic review of enteric [[dysbiosis]] in chronic fatigue syndrome/myalgic encephalomyelitis<ref>{{Cite journal|last=Du Preez|first=S.|author-link=|last2=Corbitt|first2=M.|author-link2=|last3=Cabanas|first3=H.|author-link3=Hélène Cabanas|last4=Eaton|first4=N.|author-link4=|last5=Staines|first5=D.|author-link5=Donald Staines|last6=Marshall-Gradisnik|first6=S.|author-link6=Sonya Marshall-Gradisnik|date=2018-12-20|title=A systematic review of enteric dysbiosis in chronic fatigue syndrome/myalgic encephalomyelitis|url=https://doi.org/10.1186/s13643-018-0909-0|journal=Systematic Reviews|volume=7|issue=1|pages=241|doi=10.1186/s13643-018-0909-0|issn=2046-4053|pmc=|pmid=30572962|quote=|via=}}</ref> - [https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-018-0909-0 (Full text)]
* 2018, [[Rituximab]] impedes [[natural killer cell]] function in [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]] patients: A pilot in vitro investigation<ref>{{Cite journal|title=Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation|url=https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-018-0203-8|journal=BMC Pharmacology and Toxicology|date=Dec 2018|issn=2050-6511|pmc=5870391|pmid=29587879|pages=12|volume=19|issue=1|doi=10.1186/s40360-018-0203-8|language=en|first=Natalie|last=Eaton|first2=Hélène|last2=Cabanas|first3=Cassandra|last3=Balinas|first4=Anne|last4=Klein|first5=Donald|last5=Staines|first6=Sonya|last6=Marshall-Gradisnik|quote=|last7=|first7=|last8=|first8=|author-link=|author-link2=Hélène Cabanas|access-date=|author-link3=|author-link4=|author-link5=Donald Staines|author-link6=Sonya Marshall-Gradisnik|via=}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870391/ (Full Text)]
* 2018, Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients<ref>{{Cite journal|last=Cabanas|first=Hélène|author-link=Hélène Cabanas|last2=Muraki|first2=Katsuhiko|last3=Eaton|first3=Natalie|last4=Balinas|first4=Cassandra|last5=Staines|first5=Donald|author-link5=Donald Staines|last6=Marshall-Gradisnik|first6=Sonya|author-link6=Sonya Marshall-Gradisnik|date=2018-08-14|title=Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients|url=https://molmed.biomedcentral.com/articles/10.1186/s10020-018-0046-1|journal=Molecular Medicine|language=En|volume=24|issue=1|pages=|doi=10.1186/s10020-018-0046-1|issn=1076-1551|via=}}</ref> - [https://molmed.biomedcentral.com/articles/10.1186/s10020-018-0046-1 (Full Text)]
* 2018, Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients<ref>{{Cite journal|last=Cabanas|first=Hélène|author-link=Hélène Cabanas|last2=Muraki|first2=Katsuhiko|last3=Eaton|first3=Natalie|last4=Balinas|first4=Cassandra|last5=Staines|first5=Donald|author-link5=Donald Staines|last6=Marshall-Gradisnik|first6=Sonya|author-link6=Sonya Marshall-Gradisnik|date=2018-08-14|title=Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients|url=https://molmed.biomedcentral.com/articles/10.1186/s10020-018-0046-1|journal=Molecular Medicine|language=En|volume=24|issue=1|pages=|doi=10.1186/s10020-018-0046-1|issn=1076-1551|via=}}</ref> - [https://molmed.biomedcentral.com/articles/10.1186/s10020-018-0046-1 (Full Text)]
* 2019, Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients<ref>{{Cite journal|last=Cabanas|first=H.|author-link=Hélène Cabanas|last2=Muraki|first2=K.|author-link2=|last3=Balinas|first3=C.|author-link3=|last4=Eaton-Fitch|first4=N.|author-link4=|last5=Staines|first5=D.|author-link5=Donald Staines|last6=Marshall-Gradisnik|first6=S.|author-link6=Sonya Marshall-Gradisnik|date=Dec 2019|title=Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients|url=https://molmed.biomedcentral.com/articles/10.1186/s10020-019-0083-4|journal=Molecular Medicine|language=en|volume=25|issue=1|pages=|doi=10.1186/s10020-019-0083-4|issn=1076-1551|quote=|via=}}</ref> - [https://link.springer.com/article/10.1186/s10020-019-0083-4 (Full text)]
* 2019, Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients<ref>{{Cite journal|last=Cabanas|first=H.|author-link=Hélène Cabanas|last2=Muraki|first2=K.|author-link2=|last3=Balinas|first3=C.|author-link3=|last4=Eaton-Fitch|first4=N.|author-link4=|last5=Staines|first5=D.|author-link5=Donald Staines|last6=Marshall-Gradisnik|first6=S.|author-link6=Sonya Marshall-Gradisnik|date=Dec 2019|title=Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients|url=https://molmed.biomedcentral.com/articles/10.1186/s10020-019-0083-4|journal=Molecular Medicine|language=en|volume=25|issue=1|pages=|doi=10.1186/s10020-019-0083-4|issn=1076-1551|quote=|via=}}</ref> - [https://link.springer.com/article/10.1186/s10020-019-0083-4 (Full text)]
* 2019, A systematic review of [[Cytokine|cytokines]] in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID)<ref>{{Cite journal|last=Corbitt|first=Matthew|author-link=|last2=Eaton-Fitch|first2=Natalie|author-link2=|last3=Staines|first3=Donald|author-link3=Donald Staines|last4=Cabanas|first4=Hélène|author-link4=Hélène Cabanas|last5=Marshall-Gradisnik|first5=Sonya|author-link5=Sonya Marshall-Gradisnik|last6=|first6=|author-link6=|last7=|first7=|last8=|first8=|date=Dec 2019|title=A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID)|url=https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-019-1433-0|journal=BMC Neurology|language=en|volume=19|issue=1|pages=|doi=10.1186/s12883-019-1433-0|issn=1471-2377|pmc=|pmid=31445522|access-date=|quote=|via=}}</ref> - [https://link.springer.com/article/10.1186/s12883-019-1433-0#citeas (Full text)]
* 2019, A systematic review of [[Cytokine|cytokines]] in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID)<ref>{{Cite journal|last=Corbitt|first=Matthew|author-link=|last2=Eaton-Fitch|first2=Natalie|author-link2=|last3=Staines|first3=Donald|author-link3=Donald Staines|last4=Cabanas|first4=Hélène|author-link4=Hélène Cabanas|last5=Marshall-Gradisnik|first5=Sonya|author-link5=Sonya Marshall-Gradisnik|last6=|first6=|author-link6=|last7=|first7=|last8=|first8=|date=Dec 2019|title=A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID)|url=https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-019-1433-0|journal=BMC Neurology|language=en|volume=19|issue=1|pages=|doi=10.1186/s12883-019-1433-0|issn=1471-2377|pmc=|pmid=31445522|access-date=|quote=|via=}}</ref> - [https://link.springer.com/article/10.1186/s12883-019-1433-0#citeas (Full text)]


* 2019, Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients
* 2019, Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients - [https://www.frontiersin.org/articles/10.3389/fimmu.2019.02545/abstract (Abstract)]


==Clinic location==
==Clinic location==

Revision as of 21:08, October 21, 2019

Hélène Cabanas, PhD, is a Cell physiologist participating in a post-doctorate fellowship at the School of Medical Sciences, Griffith Health, Griffith University, Australia.[1] She is a member of the National Centre for Neuroimmunology and Emerging Disease (NCNED), an Australian research group led by Professors Sonya Marshall-Gradisnik and Donald Staines.[2] Her research focuses on cellular calcium pathway signalling and their implications in physiological and pathophysiological processes in hopes of understanding the pathomechanism of Chronic Fatigue Syndrome / Myalgic Encephalomyelitis (CFS/ME).[2]

Notable studies[edit | edit source]

  • 2019, Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients - (Abstract)

Clinic location[edit | edit source]

Talks and interviews[edit | edit source]

Online presence[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. "Hélène Cabanas". LinkedIn. Retrieved October 21, 2019. Cite has empty unknown parameter: |dead-url= (help)
  2. 2.0 2.1 "National Centre for Neuroimmunology and Emerging Diseases". www.griffith.edu.au. Retrieved October 21, 2019.
  3. Marshall-Gradisnik, Sonya; Fretel, Marshall; Eaton, Natalie; Cabanas, Helene; Balinas, Cassandra; Gopalan, Vinod; Petersen, Daniel; Passmore, Rachel; Tang, Kevin; Haque, Mazhar; Lam, Alfred; Staines, Donald (May 31, 2018). "Decreased Expression of TRPM3 and mAChRM3 in the Small Intestine in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis". International Journal of Clinical Medicine. 09 (05): 467. doi:10.4236/ijcm.2018.95040.
  4. Du Preez, S.; Corbitt, M.; Cabanas, H.; Eaton, N.; Staines, D.; Marshall-Gradisnik, S. (December 20, 2018). "A systematic review of enteric dysbiosis in chronic fatigue syndrome/myalgic encephalomyelitis". Systematic Reviews. 7 (1): 241. doi:10.1186/s13643-018-0909-0. ISSN 2046-4053. PMID 30572962.
  5. Eaton, Natalie; Cabanas, Hélène; Balinas, Cassandra; Klein, Anne; Staines, Donald; Marshall-Gradisnik, Sonya (December 2018). "Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation". BMC Pharmacology and Toxicology. 19 (1): 12. doi:10.1186/s40360-018-0203-8. ISSN 2050-6511. PMC 5870391. PMID 29587879.
  6. Cabanas, Hélène; Muraki, Katsuhiko; Eaton, Natalie; Balinas, Cassandra; Staines, Donald; Marshall-Gradisnik, Sonya (August 14, 2018). "Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients". Molecular Medicine. 24 (1). doi:10.1186/s10020-018-0046-1. ISSN 1076-1551.
  7. Cabanas, H.; Muraki, K.; Balinas, C.; Eaton-Fitch, N.; Staines, D.; Marshall-Gradisnik, S. (December 2019). "Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients". Molecular Medicine. 25 (1). doi:10.1186/s10020-019-0083-4. ISSN 1076-1551.
  8. Corbitt, Matthew; Eaton-Fitch, Natalie; Staines, Donald; Cabanas, Hélène; Marshall-Gradisnik, Sonya (December 2019). "A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID)". BMC Neurology. 19 (1). doi:10.1186/s12883-019-1433-0. ISSN 1471-2377. PMID 31445522.